Skip to content

Ginkgo Bioworks DNA Loans Receivable Fair Value Disclosure

Loans Receivable Fair Value Disclosure at other companies

Blackstone logo
BlackstoneBX
$425.98M+270%
Paccar logo
PaccarPCAR
$9.94B+7.8%
Apollo Global Management logo
Apollo Global ManagementAPO
$296M-5.4%
The Bancorp logo
The BancorpTBBK
$34.7M+163%
KEE
Keel Infrastructure Corp. Common StockKEEL
$5.47M+335%
Trinity Capital logo
Trinity CapitalTRIN
$24.4M+60.5%

Other financials

Income statement

See full
Revenue$19.5M-49.1%
Gross profit$16.4M-52.0%
Operating income-$71.4M+11.9%
Net income-$82.6M+9.2%
EPS (diluted)-$1.42+27.6%

Balance sheet

See full
Cash & equivalents$188.7M-46.9%
Total debt$410.7M-5.5%
Total equity$443.2M-31.6%
Total assets$1.0B-20.1%

Cash flow

See full
Operating cash flow-$46.7M+9.4%
CapEx$1.9M-74.6%
Free cash flow-$48.6M+17.8%

Valuation

See full
Market cap$625.16M+24.6%
Enterprise value$847.19M+45.9%
P/S4.4×+2.2×

Profitability

See full
Operating margin-210.7%+7.6pp
Net margin-215.4%+8.3pp
FCF margin-119%-21.2pp

Returns & leverage

See full
Return on equity-55.8%-1.8pp
Debt / equity0.9×+0.3×
Current ratio5.2×+0.3×

Where this comes from

Reported directly by Ginkgo Bioworks in its filing.

Tagged under the XBRL concept us-gaap:LoansReceivableFairValueDisclosure.

The official record: Ginkgo Bioworks’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ginkgo Bioworks's loans receivable fair value disclosure.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ginkgo Bioworks's loans receivable fair value disclosure?
Ginkgo Bioworks (DNA) reported loans receivable fair value disclosure of $500K in Q4 2025.
How has Ginkgo Bioworks's loans receivable fair value disclosure changed year-over-year?
Ginkgo Bioworks's loans receivable fair value disclosure decreased by 96.5% year-over-year, from $14.2M to $500K.